Therapeutic Protein Players Investing Heavily in Multiple Sclerosis and Cancer
Significant advancement in genetic engineering offers global acceptance of protein products for various clinical applications so as to prevent wide variety of chronic diseases. A brief look at the pipeline of protein therapeutic producers and the recent FDA approvals obtained by them suggests that most of these players have been concentrating on cancer and multiple sclerosis. Ample of protein therapeutic products have been undergoing Phase III clinical trials for treating varied forms of cancer. Moreover, several mAbs have been evaluated...
View full press release